Hedgehog inhibition with the orally bioavailable Smo antagonist LDE225 represses tumor growth and prolongs survival in a transgenic mouse model of islet cell neoplasms.

Hedgehog inhibition with the orally bioavailable Smo antagonist LDE225 represses tumor growth and prolongs survival in a transgenic mouse model of islet cell neoplasms.

Item
http://www.wikidata.org/entity/Q34229229
PDGFRα up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation.Menin epigenetically represses Hedgehog signaling in MEN1 tumor syndrome.Chronic pancreatitis and systemic inflammatory response syndrome prevent impact of chemotherapy with gemcitabine in a genetically engineered mouse model of pancreatic cancer.Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cellsA genome scale RNAi screen identifies GLI1 as a novel gene regulating vorinostat sensitivity.Studying the role of the immune system on the antitumor activity of a Hedgehog inhibitor against murine osteosarcoma.Novel molecular targets for the treatment of gastroenteropancreatic endocrine tumors: answers and unsolved problemsHedgehog signaling pathway as a new therapeutic target in pancreatic cancer.Hedgehog inhibitor sonidegib potentiates 177Lu-octreotate therapy of GOT1 human small intestine neuroendocrine tumors in nude miceSonidegib: First Global Approval.Hedgehog signaling pathway affects the sensitivity of hepatoma cells to drug therapy through the ABCC1 transporter.Aberrant hedgehog signaling is responsible for the highly invasive behavior of a subpopulation of hepatoma cells.Medical treatment of gastroenteropancreatic neuroendocrine tumors.Exposure-Response Analysis of Sonidegib (LDE225), an Oral Inhibitor of the Hedgehog Signaling Pathway, for Effectiveness and Safety in Patients With Advanced Solid Tumors.Targeted therapy of gastroenteropancreatic neuroendocrine tumours: preclinical strategies and future targets.Sorafenib inhibits tumor growth and improves survival in a transgenic mouse model of pancreatic islet cell tumors.
P2860

Hedgehog inhibition with the orally bioavailable Smo antagonist LDE225 represses tumor growth and prolongs survival in a transgenic mouse model of islet cell neoplasms.

Item
http://www.wikidata.org/entity/Q34229229
description
2011 nî lūn-bûn
@nan
2011 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Hedgehog inhibition with the o ...... model of islet cell neoplasms.
@ast
Hedgehog inhibition with the o ...... model of islet cell neoplasms.
@en
Hedgehog inhibition with the o ...... model of islet cell neoplasms.
@nl
type
label
Hedgehog inhibition with the o ...... model of islet cell neoplasms.
@ast
Hedgehog inhibition with the o ...... model of islet cell neoplasms.
@en
Hedgehog inhibition with the o ...... model of islet cell neoplasms.
@nl
prefLabel
Hedgehog inhibition with the o ...... model of islet cell neoplasms.
@ast
Hedgehog inhibition with the o ...... model of islet cell neoplasms.
@en
Hedgehog inhibition with the o ...... model of islet cell neoplasms.
@nl
P1433
P1476
P2093
P304
P31
P356
P407
P433
P478
P577
P698
P356
P1433
P1476
Hedgehog inhibition with the o ...... model of islet cell neoplasms.
@en
P2093
P304
P31
P356
10.1097/SLA.0B013E318236BC0F
P407
P433
P478
P577
P698